Cập nhật thông tin các bệnh lý phổi do ký sinh trùng
Nhiều tác nhân ký sinh trùng có thể gây nên các triệu chứng đường hô hấp, hoặc gây hội chứng ở phế quản phổi và về mặt thực hành lâm sàng cho thấy khâu khác thác yếu tố bệnh sử và tiền sử đi du lịch đến các vùng lưu hành có thể một phần nào đó định danh và khu trú tác nhân gây bệnh cũng như các hình ảnh x quang học trên phim phổi (nếu thầy thuốc đó có kinh nghiệm).
Một số trường hợp mắc bệnh ký sinh trùng đường ruột và ký sinh trùng đơn bào ảnh hưởng đến hệ hô hấp, phổi và gây nên viêm phổi rất phổ biến ở các vùng nhiệt đới. Những ký sinh trùng thường lưu hành phổ biến nhất ở phía Tây thế giới và là những bệnh ở vật chủ thiếu/ suy giảm miễn dịch.
1.V. K. Vijayan, “Tropical parasitic lung diseases,”The Indian Journal of Chest Diseases and Allied Sciences, vol. 50, no. 1, pp. 49–66, 2008.
2.S. L. Berk and A. Verghese, “Parasitic pneumonia,”Seminars in Respiratory Infections, vol. 3, no. 2, pp. 172–178, 1988.
3.W. Loffler, “Zur differential-diagnose der lungeninfiltrieurgen: 11 Uber fluchtige succedan-infiltrate (mit eosinophile),”Beitr Klin Erforsch Tuberk Lungenkr, vol. 79, pp. 368–392, 1992.
4.V. K. Vijayan, “How to diagnose and manage common parasitic pneumonias,”Current Opinion in Pulmonary Medicine, vol. 13, no. 3, pp. 218–224, 2007.
5.A. M. Dondorp, V. Desakorn, W. Pongtavornpinyo, et al., “Estimation of the total parasite biomass in acute falciparum malaria from plasma PfHRP2,”PLoS Medicine, vol. 2, no. 8, Article ID e204, 2005.
6.Medicines for Malaria Venture, “The lifecycle of the malaria parasite,”http://www.mmv.org.
7.United States Centers for Disease Control and Prevention, http://www.cdc.gov/malaria/about/disease.
8.A. H. Fairlamb, “Future prospects for the chemotherapy of human trypanosomiasis. 1. Novel approaches to the chemotherapy of trypanosomiasis,”Transactions of the Royal Society of Tropical Medicine and Hygiene, vol. 84, no. 5, pp. 613–617, 1990.
9.G. P. Maguire, T. Handojo, M. C. F. Pain et al., “Lung injury in uncomplicated and severe falciparum malaria: a longitudinal study in Papua, Indonesia,”Journal of Infectious Diseases, vol. 192, no. 11, pp. 1966–1974, 2005.
10.M. D. Jamil, G. Kar, S. K. Biswas, and P. Kaushik, “Clinical manifestations of falciparum malaria in relation to parasitemia level in Southern Assam,”Journal of the Medical Association of India, vol. 57, 4 pages, 2009.
11.S. Mharakurwa, C. Simoloka, P. E. Thuma, C. J. Shiff, and D. J. Sullivan, “PCR detection of Plasmodium falciparum in human urine and saliva samples,”Malaria Journal, vol. 5, article 103, 2006.View at Publisher.
12.M. Sanklecha, N. Mehta, and H. Bagban, “Varied presentation of complicated falciparum malaria in a family,”Indian Pediatrics, vol. 49, no. 5, pp. 413-414, 2012.
13.P. H. O. Cabral, S. D. Andrade, W. D. Alecrim, M. G. C. Alecrim, and M. V. G. Lacerda, “Malaria and sickle cell anemia: report of complications and clinical management of three patients in a highly endemic area FOR Plasmodium vivax malaria in the Brazilian Amazon,”Case Reports and Clinical Practice Review, vol. 7, pp. 220–223, 2006.
14.J. D. Maguire, M. E. Fenton, A. I. Susanti, and J. B. Walker, “Plasmodium vivax-associated acute respiratory distress syndrome after extended travel in Afghanistan,”Travel Medicine and Infectious Disease, vol. 5, no. 5, pp. 301–305, 2007.View at Publisher.
15.S. Sarkar, K. Saha, and C. S. Das, “Three cases of ARDS: an emerging complication of Plasmodium vivax malaria,”Lung India, vol. 27, no. 3, pp. 154–157, 2010.
16.P. Charoenpan, S. Indraprasit, S. Kiatboonsri, O. Suvachittanont, and S. Tanomsup, “Pulmonary edema in severe falciparum malaria. Hemodynamic study and clinicophysiologic correlation,”Chest, vol. 97, no. 5, pp. 1190–1197, 1990.
17.E. Pongponratn, M. Riganti, B. Punpoowong, and M. Aikawa, “Microvascular sequestration of parasitized erythrocytes in human falciparum malaria: a pathological study,”The American Journal of Tropical Medicine and Hygiene, vol. 44, no. 2, pp. 168–175, 1991.
18.N. Lacerda-Queiroz, M. A. Rachid, M. M. Teixeira, and A. L. Teixeira, “The role of platelet-activating factor receptor (PAFR) in lung pathology during experimental malaria,”International Journal for Parasitology, vol. 43, no. 1, pp. 11–15, 2013.
19.B. Autino, Y. Corbett, F. Castelli, and D. Taramelli, “Pathogenesis of malaria in tissues and blood,”Mediterranean Journal of Hematology and Infectious Diseases, vol. 4, no. 1, Article ID e2012061, 2012.
20.A. Djimdé, O. K. Doumbo, J. F. Cortese et al., “A molecular marker for chloroquine-resistant falciparum malaria,”The New England Journal of Medicine, vol. 344, no. 4, pp. 257–263, 2001.
21.M. K. Laufer, P. C. Thesing, N. D. Eddington et al., “Return of chloroquine antimalarial efficacy in Malawi,”The New England Journal of Medicine, vol. 355, no. 19, pp. 1959–1966, 2006.
22.T. K. Mutabingwa, “Artemisinin-based combination therapies (ACTs): best hope for malaria treatment but inaccessible to the needy!,”Acta Tropica, vol. 95, no. 3, pp. 305–315, 2005.
23.World Health Organization,Guidelines for the Treatment of Malaria, World Health Organization, Geneva, Switzerland, 2006.
24.World Health Organization,Management of Severe Malaria: A Practical Handbook, WHO, 3rd edition, 2012,http://www.who.int/malaria.
25.K. M. Kiang, P. A. Bryant, D. Shingadia, S. Ladhani, A. C. Steer, and B. David, “The treatment of imported malaria in children: an update,”Archives of Disease in Childhood: Education and Practice Edition, vol. 98, no. 1, pp. 7–15, 2013.
26.B. M. Greenwood, K. Bojang, C. J. M. Whitty, and G. A. T. Targett, “Malaria,”The Lancet, vol. 365, no. 9469, pp. 1487–1498, 2005.
27.United States Centers for Disease Control and Prevention, “Amebiasis—biology,”http://www.cdc.gov/parasites/amebiasis/biology.html.
28.J. P. Ackers and D. Mirelman, “Progress in research on Entamoeba histolytica pathogenesis,”Current Opinion in Microbiology, vol. 9, no. 4, pp. 367-373, 2006.
29.S. M. Shamsuzzaman and Y. Hashiguchi, “Thoracic amebiasis,”Clinics in Chest Medicine, vol. 23, no. 2, pp. 479-492, 2002.
30.S. N. Moonah, N. M. Jiang, and W. A. Petri Jr., “Host immune response to intestinal amebiasis,”PLoS Pathogens, vol. 9, no. 8, Article ID e1003489, 2013.View at Publisher.
31.Hamzah, S. Petmitr, M. Mungthin, S. Leelayoova, and P. Chavalitshewinkoon-Petmitr, “Differential detection of Entamoeba histolytica, Entamoeba dispar, and Entamoeba moshkovskii by a single-round PCR assay,”Journal of Clinical Microbiology, vol. 44, no. 9, pp. 3196–3200, 2006.
32.R. Haque and W. A. Petri Jr., “Diagnosis of amebiasis in Bangladesh,”Archives of Medical Research, vol. 37, no. 2, pp. 273–276, 2006.
33.M. Tanyuksel and W. A. Petri Jr., “Laboratory diagnosis of amebiasis,”Clinical Microbiology Reviews, vol. 16, no. 4, pp. 713–729, 2003.
34.I. Garcia-Rubio, C. Martinez-Cocera, S. Santos Magadan, B. Rodriguez-Jimenez, and S. asquez-cortes, “Hypersensitivity reactions to metronidazole,”Allergologica et Immunopathologica, vol. 34, no. 2, pp. 70–72, 2006.
35.N. León-Sicairos, M. Reyes-López, C. Ordaz-Pichardo, and M. de la Garza, “Microbicidal action of lactoferrin and lactoferricin and their synergistic effect with metronidazole in Entamoeba histolytica,”Biochemistry and Cell Biology, vol. 84, no. 3, pp. 327–336, 2006.
36.H. Lotter and E. Tannich, “The current status of an amebiasis vaccine,”Archives of Medical Research, vol. 37, no. 2, pp. 292–296, 2006.
37.R. Basu, S. Roy, and P. Walden, “HLA class I-restricted T cell epitopes of the kinetoplastid membrane protein-11 presented by Leishmania donovani-infected human macrophages,”Journal of Infectious Diseases, vol. 195, no. 9, pp. 1373–1380, 2007.
38.T. V. Piscopo and A. C. Mallia, “Leishmaniasis,”Postgraduate Medical Journal, vol. 82, no. 972, pp. 649–657, 2006.
39.R. Russo, F. Laguna, R. López-Vélez et al., “Visceral leishmaniasis in those infected with HIV: clinical aspects and other opportunistic infections,”Annals of Tropical Medicine and Parasitology, vol. 97, supplement 1, pp. S99-S105, 2003.
40.A. A. Benzie, R. D. Goldin, and J. Walsh, “A case report of seronegative pulmonary leishmaniasis in an HIV-hepatitis C co-infected patient,”HIV Medicine, vol. 7, supplement 1, 36 pages, 2006, abstract no. P100.
41.J. Alvar, P. Aparicio, A. Aseffa et al., “The relationship between leishmaniasis and AIDS: the second 10 years,”Clinical Microbiology Reviews, vol. 21, no. 2, pp. 334–359, 2008.
42.V. Barreto-de-Souza, G. J. Pacheco, A. R. Silva et al., “Increased Leishmania replication in HIV-1-infected macrophages is mediated by tat protein through cyclooxygenase-2 expression and prostaglandin E 2 synthesis,”Journal of Infectious Diseases, vol. 194, no. 6, pp. 846–854, 2006.
43.G. F. Cota, M. R. de Sousa, and A. Rabello, “Predictors of visceral leishmaniasis relapse in hiv-infected patients: a systematic review,”PLoS Neglected Tropical Diseases, vol. 5, no. 6, Article ID e1153, 2011.
44.J. R. Santos-Oliveira, C. B. W. Giacoia-Gripp, P. de Oliveira et al., “High levels of T lymphocyte activation in Leishmania-HIV-1 co-infected individuals despite low HIV viral load,”BMC Infectious Diseases, vol. 10, pp. 358–363, 2010.
45.P. Alexandrino-de-Oliveira, J. R. Santos-Oliveira, M. E. C. Dorval et al., “HIV/AIDS-associated visceral leishmaniasis in patients from an endemic area in Central-west Brazil,”Memorias do Instituto Oswaldo Cruz, vol. 105, no. 5, pp. 692–697, 2010.
46.P. Morales, J. J. Torres, M. Salavert, J. Pemán, J. Lacruz, and A. Solé, “Visceral leishmaniasis in lung transplantation,”Transplantation Proceedings, vol. 35, no. 5, pp. 2001–2003, 2003.
47.J. R. Santos-Oliveira and A. M. Da-Cruz, “Lipopolysaccharide-induced cellular activation may participate in the immunopathogenesis of visceral leishmaniasis alone or in HIV coinfection,”International Journal of Microbiology, vol. 2012, Article ID 364534, 4 pages, 2012.
48.S. L. Croft and J. Engel, “Miltefosine—discovery of the antileishmanial activity of phospholipid derivatives,”Transactions of the Royal Society of Tropical Medicine and Hygiene, vol. 100, supplement 1, pp. 54–58, 2006.
49.R. Sachdeva, A. C. Banerjea, N. Malla, and M. L. Dubey, “Immunogenicity and efficacy of single antigen Gp63, polytope and polytopeHSP70 DNA vaccines against visceral leishmaniasis in experimental mouse model,”PLoS onE, vol. 4, no. 12, Article ID e7880, 2009.
50.B. Bouteille and A. Buguet, “The detection and treatment of human African trypanosomiasis,”Research and Reports in Tropical Medicine, vol. 3, pp. 35–45, 2012.
51.M. Ayub, S. A. Shah SA, M. Irfan, J. A. Khan, and S. N. Hashmi, “A case of human African trypanosomiasis during United Nation Mission in Liberia,”Pakistan Armed Forces Medical Journal, vol. 8, no. 1, 2011.
52.V. G. Melnikov, F. F. Velasco, F. E. Gómez, F. G. Rodríguez, and O. R. Dobrovinskaya, “Pathologic changes in lungs caused by Mexican isolates of Trypanosoma cruzi in the acute phase of infection in mice,”The American Journal of Tropical Medicine and Hygiene, vol. 73, no. 2, pp. 301-306, 2005.
53.M. S. Šíma, H. Havelková, L. Quan, et al., “Genetic control of resistance to Trypanosoma brucei infection in mice,”PLoS Neglected Tropical Diseases, vol. 5, no. 6, Article ID e1173, 2011.
54.D. Biswas, A. Choudhury, and K. K. Misra, “Histopathology of Trypanosoma (Trypanozoon) evansi infection in bandicoot rat. I. Visceral organs,”Experimental Parasitology, vol. 99, no. 3, pp. 148–159, 2001.
55.M. D. C. Pereira Nuñes, M. de Melo Barbosa, V. A. Andrade Brum, and M. O. da Costa Rocha, “Morphofunctional characteristics of the right ventricle in Chagas' dilated cardiomyopathy,”International Journal of Cardiology, vol. 94, no. 1, pp. 79–85, 2004.
56.J. Pépin, N. Khonde, F. Maiso et al., “Short-course eflornithine in Gambian trypanosomiasis: a multicentre randomized controlled trial,”Bulletin of the World Health Organization, vol. 78, no. 11, pp. 1284–1295, 2000.
57.F. W. Jennings, “Future prospects for the chemotherapy of human trypanosomiasis. 2. Combination chemotherapy and African trypanosomiasis,”Transactions of the Royal Society of Tropical Medicine and Hygiene, vol. 84, no. 5, pp. 618–621, 1990.
58.C. N. Paiva, D. F. Feijó, F. F. Dutra et al., “Oxidative stress fuels Trypanosoma cruzi infection in mice,”The Journal of Clinical Investigation, vol. 122, no. 7, pp. 2531–2542, 2012.
59.G. J. Feldman and H. W. Parker, “Visceral larva migrans associated with the hypereosinophilic syndrome and the onset of severe asthma,”Annals of Internal Medicine, vol. 116, no. 10, pp. 838–840, 1992.
60.J. Roig, J. Romeu, C. Riera, A. Texido, C. Domingo, and J. Morera, “Acute eosinophilic pneumonia due to toxocariasis with bronchoalveolar lavage findings,”Chest, vol. 102, no. 1, pp. 294–296, 1992.
61.A. K. M. Bartelink, L. M. Kortbeek, H. J. Huidekoper, J. Meulenbelt, and F. van Knapen, “Acute respiratory failure due to toxocara infection,”The Lancet, vol. 342, no. 8881, p. 1234, 1993.
62.J. F. Magnaval, L. T. Glickman, P. Dorchies, and B. Morassin, “Highlights of human toxocariasis,”Korean Journal of Parasitology, vol. 39, no. 1, pp. 1–11, 2001.
63.L. T. Glickman, J.-F. Magnaval, L. M. Domanski et al., “Visceral larva migrans in French adults: a new disease syndrome?”The American Journal of Epidemiology, vol. 125, no. 6, pp. 1019–1034, 1987.
64.D. Nathwani, R. B. S. Laing, and P. F. Currie, “Covert toxocariasis—a cause of recurrent abdominal pain in childhood,”British Journal of Clinical Practice, vol. 46, no. 4, p. 271, 1992.
65.J.-F. Magnaval, R. Fabre, P. Maurieres, J.-P. Charlet, and B. de Larrard, “Evaluation of an immunoenzymatic assay detecting specific anti-Toxocara immunoglobulin E for diagnosis and posttreatment follow-up of human toxocariasis,”Journal of Clinical Microbiology, vol. 30, no. 9, pp. 2269–2274, 1992.
66.J.-F. Magnaval, R. Fabre, P. Maurieres, J.-P. Charlet, and B. de Larrard, “Application of the Western blotting procedure for the immunodiagnosis of human toxocariasis,”Parasitology Research, vol. 77, no. 8, pp. 697–702, 1991.
67.L. N. Rasmussen, M. Dirdal, and N. H. Birkebaek, “‘Covert toxocariasis’ in a child treated with low-dose diethylcarbamazine,”Acta Paediatrica, International Journal of Paediatrics, vol. 82, no. 1, pp. 116–118, 1993.
68.J.-F. Magnaval, “Comparative efficacy of diethylcarbamazine and mebendazole for the treatment of human toxocariasis,”Parasitology, vol. 110, part 5, pp. 529–533, 1995.
69.D. Sturchler, P. Schubarth, M. Gualzata, B. Gottstein, and A. Oettli, “Thiabendazole vs. albendazole in treatment of toxocariasis: a clinical trial,”Annals of Tropical Medicine and Parasitology, vol. 83, no. 5, pp. 473–478, 1989.
70.E. M. Dodds, “Toxoplasmosis,”Current Opinion in Ophthalmology, vol. 17, no. 6, pp. 557–561, 2006.
71.E. Monsó, R. Vidal, X. de Gracia, and A. Moragas, “Pulmonary toxoplasmoma presenting as obstructive pneumonia,”Thorax, vol. 41, no. 6, pp. 489–490, 1986.
72.G. Nash, R. L. Kerschmann, B. Herndier, and J. P. Dubey, “The pathological manifestations of pulmonary toxoplasmosis in the acquired immunodeficiency syndrome,”Human Pathology, vol. 25, no. 7, pp. 652–658, 1994.
73.S. Laibe, S. Ranque, C. Curtillet, F. Faraut, H. Dumon, and J. Franck, “Timely diagnosis of disseminated toxoplasmosis by sputum examination,”Journal of Clinical Microbiology, vol. 44, no. 2, pp. 646–648, 2006.
74.E. Petersen, B. Edvinsson, B. Lundgren, T. Benfield, and B. Evengård, “Diagnosis of pulmonary infection with Toxoplasma gondii in immunocompromised HIV-positive patients by real-time PCR,”European Journal of Clinical Microbiology and Infectious Diseases, vol. 25, no. 6, pp. 401–404, 2006.
75.P. J. Krause, “Babesiosis,”Medical Clinics of North America, vol. 86, no. 2, pp. 361–373, 2002.
76.S. J. Swanson, D. Neitzel, K. D. Reed, and E. A. Belongia, “Coinfections acquired from Ixodes ticks,”Clinical Microbiology Reviews, vol. 19, no. 4, pp. 708–727, 2006.
77.M. R. Boustani, T. J. Lepore, J. A. Gelfand, and D. S. Lazarus, “Acute respiratory failure in patients treated for babesiosis,”The American Journal of Respiratory and Critical Care Medicine, vol. 149, no. 6, pp. 1689–1691, 1994.
78.M. L. Horowitz, F. Coletta, and A. M. Fein, “Delayed onset adult respiratory distress syndrome in babesiosis,”Chest, vol. 106, no. 4, pp. 1299–1301, 1994.
79.P. J. Krause, “Babesiosis diagnosis and treatment,”Vector Borne and Zoonotic Diseases, vol. 3, no. 1, pp. 45–51, 2003.
80.M. Raju, J. C. Salazar, H. Leopold, and P. J. Krause, “Atovaquone and azithromycin treatment for babesiosis in an infant,”Pediatric Infectious Disease Journal, vol. 26, no. 2, pp. 181–183, 2007.
81.V. K. Vijayan, “Tropical pulmonary eosinophilia: pathogenesis, diagnosis and management,”Current Opinion in Pulmonary Medicine, vol. 13, no. 5, pp. 428–433, 2007.
82.E. A. Ottesen, “Immunological aspects of lymphatic filariasis and onchocerciasis in man,”Transactions of the Royal Society of Tropical Medicine and Hygiene, vol. 78, pp. 9–18, 1984.
83.C. Frimodt-Möller and R. M. Barton, “A pseudo-tuberculosis condition associated with eosinophilia,”Indian Medical Gazette, vol. 75, no. 10, pp. 607–613, 1940.
84.R. J. Weingarten, “Tropical eosinophilia,”The Lancet, vol. 241, no. 6230, pp. 103–105, 1943.
85.S. R. Kamat, B. D. Pimparkar, S. D. Store, N. V. Warrier, and Y. C. Fakey, “Study of clinical, radiological and pulmonary function patterns of response to treatment in pulmonary eosinophilia,”The Indian Journal of Chest Diseases, vol. 12, no. 3, pp. 91–100, 1970.
86.S. P. Basu, “X-ray appearance in lung fields in tropical eosinophilia,”Indian Medical Gazette, vol. 89, pp. 212–217, 1954.
87.N. Islam and K. S. Huque, “Radiological features of tropical eosinophilia,”Journal of Tropical Medicine and Hygiene, vol. 68, pp. 117–180, 1965.
88.F. Y. Khoo and T. J. Danaraj, “The roentgenographic appearance of eosinophilic lung (tropical eosinophilia),”The American Journal of Roentgenology, Radium Therapy, and Nuclear Medicine, vol. 83, pp. 251–259, 1960.
89.World Health Organization, Division of Control of Tropical Diseases,Lymphatic Filariasis Infection and Disease: Control Strategies, (TDR/CTD/FIL/Penang), 1994.
90.M. Sandhu, S. Mukhopadhyay, and S. K. Sharma, “Tropical pulmonary eosinophilia: a comparative evaluation of plain chest radiography and computed tomography,”Australasian Radiology, vol. 40, no. 1, pp. 32–37, 1996.
91.S. Johnson, R. Wilkinson, and R. N. Davidson, “Tropical respiratory medicine. 4. Acute tropical infections and the lung,”Thorax, vol. 49, no. 7, pp. 714–718, 1994.
92.E. A. Ottesen and T. B. Nutman, “Tropical pulmonary eosinophilia,”Annual Review of Medicine, vol. 43, pp. 417–424, 1992.
93.T. J. Danaraj and J. F. Schacher, “I/D test with Dirofilaria immitis extract in eosinophilic lung (tropical eosinophilia),”The American Journal of Tropical Medicine and Hygiene, vol. 8, no. 6, pp. 640–643, 1959.
94.J. K. G. Webb, C. K. Job, and E. W. Gault, “Tropical eosinophilia: demonstration of microfilariae in lung, liver and lymph nodes,”The Lancet, vol. 275, no. 7129, pp. 835–842, 1960.
95.V. V. Joshi, F. E. Udwadia, and R. K. Gadgil, “Etiology of tropical eosinophilia. A study of lung biopsies and review of published reports,”The American Journal of Tropical Medicine and Hygiene, vol. 18, no. 2, pp. 231–240, 1969.
96.T. J. Danaraj, G. Pacheco, K. Shanmugaratnam, and P. C. Beaver, “The etiology and pathology of eosinophilic lung (tropical eosinophilia),”The American Journal of Tropical Medicine and Hygiene, vol. 15, no. 2, pp. 183–189, 1966.
97.E. A. Ottesen, F. A. Neva, R. S. Paranjape, S. P. Tripathy, K. V. Thiruvengadam, and M. A. Beaver, “Specific allergic sensitization to filarial antigens in tropical pulmonary eosinophilia,”The Lancet, vol. 314, no. 8153, pp. 1158–1161, 1979.
98.R. Viswanathan, R. C. Bagai, and R. Saran, “Leukocyte adhesion phenomenon in pulmonary eosinophilia (tropical eosinophilia),”The American Review of Respiratory Disease, vol. 107, no. 2, pp. 298–300, 1973.
99.G. Dreyer, J. Noroes, A. Rocha, and D. Addiss, “Detection of living adult Wuchereria bancrofti in a patient with tropical pulmonary eosinophilia,”Brazilian Journal of Medical and Biological Research, vol. 29, no. 8, pp. 1005–1008, 1996.
100.C. S. Perera, L. M. Perera, C. de Silva, W. Abeywickreme, A. S. Dissanaike, and M. M. Ismail, “An eosinophilic granuloma containing an adult female Wuchereria bancrofti in a patient with tropical pulmonary eosinophilia,”Transactions of the Royal Society of Tropical Medicine and Hygiene, vol. 86, no. 5, p. 542, 1992.
101.T. B. Nutman, V. K. Vijayan, P. Pinkston et al., “Tropical pulmonary eosinophilia: analysis of antifilarial antibody localized to the lung,”Journal of Infectious Diseases, vol. 160, no. 6, pp. 1042–1050, 1989.
102.V. K. Vijayan,Tropical eosinophilia: bronchoalveolar lavage and pulmonary pathophysiology in relation to treatment [Ph.D. thesis], University of Madras, Madras, India, 1988.
103.V. K. Vijayan, K. V. Kuppu Rao, K. Sankaran, P. Venkatesan, and R. Prabhakar, “Tropical eosinophilia: clinical and physiological response to diethylcarbamazine,”Respiratory Medicine, vol. 85, no. 1, pp. 17–20, 1991.
104.World Health Organization,Final Report: Joint WPRO/SEARO Working Group on Brugian Filariasis, WHO, Manila, Philippines, 1979.
105.R. D. Ganatra, U. K. Sheth, and R. A. Lewis, “Diethylcarbamazine (hetrazan) in tropical eosinophilia,”The Indian Journal of Medical Research, vol. 46, no. 2, pp. 205–222, 1958.
106.S. J. Baker, K. T. Rajan, and S. Devadatta, “Treatment of tropical eosinophilia: a controlled trial,”The Lancet, vol. 274, no. 7095, pp. 144–147, 1959.
107.F. Ciferri, “Human pulmonary dirofilariasis in the United States: a critical review,”The American Journal of Tropical Medicine and Hygiene, vol. 31, no. 2, pp. 302–308, 1982.
108.R. B. Adkins Jr. and A. H. Dao, “Pulmonary dirofilariasis: a diagnostic challenge,”Southern Medical Journal, vol. 77, no. 3, pp. 372–374, 1984.
109.P. J. Asimacopoulos, A. Katras, and B. Christie, “Pulmonary dirofilariasis; the largest single-hospital experience,”Chest, vol. 102, no. 3, pp. 851–855, 1992.
110.J. C. Darrow and E. E. Lack, “Solitary lung nodule due to dirofilaria immitis (dog “heartworm”),”Journal of Surgical oncology, vol. 16, no. 3, pp. 219–224, 1981.
111.A. J. Larrieu, I. Wiener, L. G. Gomez, and E. H. Williams, “Human pulmonary dirofilariasis presenting as a solitary pulmonary nodule,”Chest, vol. 75, no. 4, pp. 511–512, 1979.
112.W. H. Risher, E. F. Crocker, E. N. Beckman, J. B. Blalock, and J. L. Ochsner, “Pulmonary dirofilariasis. The largest single-institution experience,”Journal of Thoracic and Cardiovascular Surgery, vol. 97, no. 2, pp. 303–308, 1989.
113.A. Biswas, P. Reilly, A. Perez IV, and M. H. Yassin, “Human pulmonary dirofilariasis presenting as a solitary pulmonarynodule: a case report and a brief review of literature,”Respiratory Medicine Case Report, vol. 10, pp. 40–42, 2013.
114.O. Rena, M. Leutner, and C. Casadio, “Human pulmonary dirofilariasis: uncommon cause of pulmonary coin-lesion,”European Journal of Cardio-Thoracic Surgery, vol. 22, no. 1, pp. 157–159, 2002.
115.R. C. Neafie, D. H. Conner, and W. M. Meyers, “Dirofilariasis,” inPathology of Tropical and Extraordinary Diseases, C. H. Binford and D. H. Conner, Eds., pp. 391–396, Armed Forces Institute of Pathology, Washinton, DC, USA, 1976.
116.F. Ciferri, “Human pulmonary dirofilariasis in the West,”Western Journal of Medicine, vol. 134, no. 2, pp. 158–162, 1981.
117.R. Rodrigues-Silva, H. Moura, G. Dreyer, and L. Rey, “Human pulmonary dirofilariasis: a review,”Revista do Instituto de Medicina Tropical de São Paulo, vol. 37, no. 6, pp. 523–530, 1995.
118.E. A. Mulanovich, V. E. Mulanovich, and K. V. I. Rolston, “A case of Dirofilaria pulmonary infection coexisting with lung cancer,”Journal of Infection, vol. 56, no. 4, pp. 241–243, 2008.
119.S. Pampiglione, F. Rivasi, and S. Paolino, “Human pulmonary dirofilariasis,”Histopathology, vol. 29, no. 1, pp. 69–72, 1996.
120.S. Pampiglione, F. Rivasi, G. Angeli et al., “Dirofilariasis due to Dirofilaria repens in Italy, an emergent zoonosis: report of 60 new cases,”Histopathology, vol. 38, no. 4, pp. 344–354, 2001.
121.M. de Campos Jr., C. S. V. Barbas, L. T. B. Filomeno et al., “Human pulmonary dirofilariasis: analysis of 24 cases from Sao Paulo, Brazil,”Chest, vol. 112, no. 3, pp. 729–733, 1997.
122.T. Miyoshi, H. Tsubouchi, A. Iwasaki, T. Shiraishi, K. Nabeshima, and T. Shirakusa, “Human pulmonary dirofilariasis: a case report and review of the recent Japanese literature,”Respirology, vol. 11, no. 3, pp. 343–347, 2006.
123.L. T. Glickman, R. B. Grieve, and P. M. Schantz, “Serologic diagnosis of zoonotic pulmonary dirofilariasis,”The American Journal of Medicine, vol. 80, no. 2, pp. 161–164, 1986.
124.T. Yamashiro, A. Inoue, T. Tamiya, N. Suzuki, T. Moriki, and K. Araki, “The usefulness of immunologic methods for diagnosis and follow-up study of a case of pulmonary dirofilariasis,”Japanese Journal of Thoracic Diseases, vol. 27, no. 6, pp. 747–753, 1989.
125.N. Magono, H. Yosimatu, Y. Suzuki et al., “A case of pulmonary dirofilariasis diagnosed by biopsy, immunological tests and the clinical course without operation,”The Journal of Japanese Respiratory Society, vol. 47, no. 6, pp. 467–470, 2009.
126.A. Echeverri, R. F. Long, W. Check, and C. M. Burnett, “Pulmonary dirofilariasis,”Annals of Thoracic Surgery, vol. 67, no. 1, pp. 201–202, 1999.
127.T. Jelinek, J. Schulte-Hillen, and T. Löscher, “Human dirofilariasis,”International Journal of Dermatology, vol. 35, no. 12, pp. 872–875, 1996.
128.C. L. Daley, “Pulmonary infections in the tropics: impact of HIV infection,”Thorax, vol. 49, no. 4, pp. 370–378, 1994. View at Google Scholar·
129.R. M. Genta, “Global prevalence of strongyloidiasis: critical review with epidemiologic insights into the prevention of disseminated disease,”Reviews of Infectious Diseases, vol. 11, no. 5, pp. 755–767, 1989.
130.V. A. Neto, J. Pasternak, A. A. B. Moreira, M. I. S. Duarte, R. Campos, and L. M. A. Braz, “Strongyloides stercoralis hyperinfection in the acquired immunodeficiency syndrome,”The American Journal of Medicine, vol. 87, no. 5, pp. 602–603, 1989.
131.C. P. Conlon, A. J. Pinching, C. U. Perera, A. Moody, N. P. Luo, and S. B. Lucas, “HIV-related enteropathy in Zambia: a clinical, microbiological, and histological study,”The American Journal of Tropical Medicine and Hygiene, vol. 42, no. 1, pp. 83–88, 1990.
132.E. B. Scowden, W. Schaffner, and W. J. Stone, “Overwhelming strongyloidiasis. An unappreciated opportunistic infection,”Medicine, vol. 57, no. 6, pp. 527–544, 1978.
133.M. M. Gompels, J. Todd, B. S. Peters, J. Main, and A. J. Pinching, “Disseminated strongyloidiasis in AIDS: uncommon but important,”AIDS, vol. 5, no. 3, pp. 329–332, 1991.
134.O. Armignacco, A. Capecchi, P. de Mori, and L. R. Grillo, “Strongyloides stercoralis hyperinfection and the acquired immunodeficiency syndrome,”The American Journal of Medicine, vol. 86, no. 2, p. 258, 1989.
135.S. Maayan, G. P. Wormser, J. Widerhorn, E. R. Sy, Y. H. Kim, and J. A. Ernst, “Strongyloides stercoralis hyperinfection in a patient with the acquired immune deficiency syndrome,”The American Journal of Medicine, vol. 83, no. 5, pp. 945–948, 1987.
136.D. W. T. Crompton, “How much human helminthiasis is there in the world?”Journal of Parasitology, vol. 85, no. 3, pp. 397–403, 1999.
137.W. Peng, X. Zhou, and R. B. Gasser, “Ascaris egg profiles in human faeces: biological and epidemiological implications,”Parasitology, vol. 127, part 3, pp. 283–290, 2003.
138.M. Yaziciolu, Ü. Önş, and I. Yalçin, “Peripheral and nasal eosinophilia and serum total immunoglobulin e levels in children with ascariasis,”Turkish Journal of Pediatrics, vol. 38, no. 4, pp. 477–484, 1996.
139.A. Santra, T. Bhattacharya, A. Chowdhury et al., “Serodiagnosis of ascariasis with specific IgG4 antibody and its use in an epidemiological study,”Transactions of the Royal Society of Tropical Medicine and Hygiene, vol. 95, no. 3, pp. 289–292, 2001.
140.R. M. Ford, “Transient pulmonary eosinophilia and asthma: a review of 20 cases occurring in 5, 702 asthma sufferers,”The American Review of Respiratory Diseases, vol. 93, no. 5, pp. 797–803, 1996.
141.L. X. Liu and P. F. Weller, “Strongyloidiasis and other intestinal nematode infections,”Infectious Disease Clinics of North America, vol. 7, no. 3, pp. 655–682, 1993.
142.L. A. Citro, M. E. Gordon, and W. T. Miller, “Eosinophilic lung disease (or how to slice P.I.E.),”The American Journal of Roentgenology, Radium Therapy and Nuclear Medicine, vol. 117, no. 4, pp. 787–797, 1973.
143.K. E. Hoagland and G. A. Schad, “Necator americanus and Ancylostoma duodenale: life history parameters and epidemiological implications of two sympatric hookworms of humans,”Experimental Parasitology, vol. 44, no. 1, pp. 36–49, 1978.
144.P. Hotez, “Human hookworm infection,” inIntestinal Helminths, M. J. G. Farthing, G. T. Keusch, and D. Wakelin, Eds., pp. 129–150, Chapman and Hall, London, UK, 1995.
145.T. A. Nawalinski and G. A. Schad, “Arrested development in Ancylostoma duodenale: course of a self induced infection in man,”The American Journal of Tropical Medicine and Hygiene, vol. 23, no. 5, pp. 895–898, 1974.
146.M. Cappello, L. P. Clyne, P. McPhedran, and P. J. Hotez, “Ancylostoma factor Xa inhibitor: partial purification and its identification as a major hookworm-derived anticoagulant in vitro,”Journal of Infectious Diseases, vol. 167, no. 6, pp. 1474–1477, 1993.
147.F. Nakamura-Uchiyama, H. Mukae, and Y. Nawa, “Paragonimiasis: a Japanese perspective,”Clinics in Chest Medicine, vol. 23, no. 2, pp. 409–420, 2002. View at Publisher·
148.D. Blair, Z.-B. Xu, and T. Agatsuma, “Paragonimiasis and the genus Paragonimus,”Advances in Parasitology, vol. 42, pp. 113–222, 1999.
149.C. H. King, “Pulmonary flukes,” inLung Biology in Health and Disease: Parasitic Lung Disease, A. A. F. Mahamoud, Ed., pp. 157–169, Marcel Dekker, New York, NY, USA, 1997.
150.T. S. Singh, H. Sugiyama, and A. Rangsiruji, “Paragonimus & paragonimiasis in India,”Indian Journal of Medical Research, vol. 136, no. 2, pp. 192–204, 2012.
151.L. Hasdiraz, F. Oǧuzkaya, and M. Bilgin, “Is lobectomy necessary in the treatment of pulmonary hydatid cysts?”ANZ Journal of Surgery, vol. 76, no. 6, pp. 488-90, 2006.
152.Z. B. Xu, “Studies on clinical manifestations, diagnosis and control of paragonimiasis in China,”Southeast Asian Journal of Tropical Medicine and Public Health, vol. 22, supplement 1, pp. 345–348, 1991.
153.I. P. Oloyede, G. B. Inah, D. E. Bassey, and E. E. Ekanem, “Comparative study of radiological findings in pulmonary tuberculosis and paragonimiasis in children in a Southern Nigeria fishing community,”West African Journal of Radiology, vol. 21, no. 1, pp. 17–20, 2014.
154.H. Mukae, H. Taniguchi, N. Matsumoto et al., “Clinicoradiologic features of pleuropulmonary Paragonimus westermani on Kyusyu Island, Japan,”Chest, vol. 120, no. 2, pp. 514–520, 2001.
155.R. Suwanik and C. Harinasuta, “Pulmonary paragonimiasis: an evaluation of roentgen findings in 38 positive sputum patients in an endemic area in Thailand,”The American Journal of Roentgenology, vol. 81, no. 2, pp. 236–244, 1959.
156.K. Jeon, W. Koh, H. Kim et al., “Clinical features of recently diagnosed pulmonary paragonimiasis in Korea,”Chest, vol. 128, no. 3, pp. 1423–1430, 2005. View at Publisher.
157.T. N. Singh, S. Kananbala, and K. S. Devi, “Pleuropulmonary paragonimiasis mimicking pulmonary tuberculosis- A report of three cases,”Indian Journal of Medical Microbiology, vol. 23, no. 2, pp. 131–134, 2005.
158.J. Gómez-Seco, M. J. Rodríguez-Guzmán, M. J. Rodríguez-Nieto, P. F. Gómez-Escolar, T. Presa-Abos, and J. Fortes-Alen, “Pulmonary paragonimiasis,”Archivos de Bronconeumologia, vol. 47, no. 12, pp. 610–612, 2011.
159.E. Schwartz, J. Rozenman, and M. Perelman, “Pulmonary manifestations of early schistosome infection among nonimmune travelers,”The American Journal of Medicine, vol. 109, no. 9, pp. 718–722, 2000.
160.E. Lee, B. Na, Y. Bae et al., “Identification of immunodominant excretory-secretory cysteine proteases of adult Paragonimus westermani by proteome analysis,”Proteomics, vol. 6, no. 4, pp. 1290–1300, 2006.
161.B. Na, S. Kim, E. Lee et al., “Critical roles for excretory-secretory cysteine proteases during tissue invasion of Paragonimus westermani newly excysted metacercariae,”Cellular Microbiology, vol. 8, no. 6, pp. 1034–1046, 2006.
162.C. Wongkham, P. M. Intapan, W. Maleewong, and M. Miwa, “Evaluation of human IgG subclass antibodies in the serodiagnosis of paragonimiasis heterotremus,”Asian Pacific Journal of Allergy and Immunology, vol. 23, no. 4, pp. 205–211, 2005.
163.J. Song, G. Hong, J. U. Song, et al., “A case of pleural paragonimiasis confused with tuberculous pleurisy,”Tuberculosis and Respiratory Diseases, vol. 76, no. 4, pp. 175–178, 2014.
164.I. D. Vélez, J. E. Ortega, and L. E. Velásquez, “Paragonimiasis: a review from Columbia,”Clinics in Chest Medicine, vol. 23, no. 2, pp. 421–431, 2002.
165.J. Keiser, D. Engels, G. Büscher, and J. Utzinger, “Triclabendazole for the treatment of fascioliasis and paragonimiasis,”Expert Opinion on Investigational Drugs, vol. 14, no. 12, pp. 1513–1526, 2005.
166.E. Schwartz, “Pulmonary schistosomiasis,”Clinics in Chest Medicine, vol. 23, no. 2, pp. 433–443, 2002.
167.F. Walt, “The Katayama syndrome,”South African Medical Journal, vol. 28, no. 5, pp. 89–93, 1954.
168.S. A. Baharoon, H. H. Al-Jahdali, H. S. Bamefleh, A. M. Elkeir, and N. M. Yamani, “Acute pulmonary schistosomiasis,”Journal of Global Infectious Diseases, vol. 3, no. 3, pp. 293–295, 2011.
169.J. F. Doherty, A. H. Moody, and S. G. Wright, “Katayama fever: an acute manifestation of schistosomiasis,”British Medical Journal, vol. 313, no. 7064, pp. 1071–1072, 1996.
170.T. Niemann, H. P. Marti, S. H. Duhnsen, and G. Bongartz, “Pulmonary schistosomiasis-imaging features,”Journal of Radiology Case Reports, vol. 4, no. 9, pp. 37–43, 2010.
171.L. Nguyen, J. Estrella, E. A. Jett, E. L. Grunvald, L. Nicholson, and D. L. Levin, “Acute schistosomiasis in nonimmune travelers: chest CT findings in 10 patients,”The American Journal of Roentgenology, vol. 186, no. 5, pp. 1300–1303, 2006.
172.M. S. Lapa, E. V. Ferreira, C. Jardim, B. D. C. Martins, J. S. Arakaki, and R. Souza, “Clinical characteristics of pulmonary hypertension patients in two reference centers in the city of Sao Paulo,”Revista da Associacao Medica Brasileira, vol. 52, no. 3, pp. 139–143, 2006.
173.W. Morris and C. M. Knauer, “Cardiopulmonary manifestations of schistosomiasis,”Seminars in Respiratory Infections, vol. 12, no. 2, pp. 159–170, 1997.
174.S. I. Sersar, R. A. Albumaaty, H. A. Elnahas et al., “A diagnostic dilemma of right lower lobe collapse caused by pulmonary bilharsiasis,”Heart Lung and Circulation, vol. 15, no. 1, pp. 50–52, 2006.
175.G. Butrous, “Schistosomiasis pulmonary hypertension: the forgotten disease,”Egyptian Journal of Bronchology, vol. 2, no. 1, pp. 143–146, 2008.
176.R. de Amorim Correa, M. V. S. C. Moreira, J. M. da Silva Saraiva, E. V. Mancuzo, L. C. dos Santos Silva, and J. R. Lambertucci, “Treatment of schistosomiasis-associated pulmonary hypertension,”Jornal Brasileiro de Pneumologia, vol. 37, no. 2, pp. 272–276, 2011.
177.United States Centers for Disease Control and Prevention, “Echinococcosis - biology,” http://www.cdc.gov/parasites/echinococcosis/biology.html.
178.B. Gottstein and J. Reichen, “Hydatid lung disease (echinococcosis/hydatidosis),”Clinics in Chest Medicine, vol. 23, no. 2, pp. 397–408, 2002.
179.A. Kuzucu, “Parasitic diseases of the respiratory tract,”Current Opinion in Pulmonary Medicine, vol. 12, no. 3, pp. 212–221, 2006.
180.R. A. Fanne, M. Khamaisi, D. Mevorach et al., “Spontaneous rupture of lung echinococcal cyst causing anaphylactic shock and respiratory distress syndrome,”Thorax, vol. 61, no. 6, p. 550, 2006.
181.D. M. Savani and O. P. Sharma, “Eosinophilic lung disease in the tropics,”Clinics in Chest Medicine, vol. 23, no. 2, pp. 377–396, 2002.
182.A. Ito, Y. Sako, H. Yamasaki et al., “Development of Em18-immunoblot and Em18-ELISA for specific diagnosis of alveolar echinococcosis,”Acta Tropica, vol. 85, no. 2, pp. 173–182, 2003.
183.S. J. Santivañez, P. Arias, M. Portocarrero et al., “Serological diagnosis of lung cystic hydatid disease using the synthetic p176 peptide,”Clinical and Vaccine Immunology, vol. 19, no. 6, pp. 944–947, 2012.
184.M. Gencer and E. Ceylan, “Pulmonary echinococcosis with multiple nodules mimicking metastatic lung tumor in chest radiography,”Respiration, vol. 75, no. 3, p. 345, 2008.
185.T. Asanuma, T. Kawahara, O. Inanami et al., “Magnetic resonance imaging of alveolar echinococcosis experimentally induced in the rat lung,”Journal of Veterinary Medical Science, vol. 68, no. 1, pp. 15–20, 2006.
186.E. Cakir, S. E. Ozaydin, E. Tasci, and R. Baran, “Unusual presentation of hydatid cyst: diagnosis with bronchoscopy,”Journal of Infection in Developing Countries, vol. 4, no. 5, pp. 352–354, 2010.
187.B. Gottstein and J. Reichen, “Hydatid lung disease,” inLung Biology in Health and Disease: tropical Lung Disease, O. P. Sharma, Ed., pp. 327–350, Taylor and Francis Group, New York, NY, USA, 2nd edition, 2006.
188.S. Kavukcu, D. Kilic, A. O. Tokat et al., “Parenchyma-preserving surgery in the management of pulmonary hydatid cysts,”Journal of Investigative Surgery, vol. 19, no. 1, pp. 61 - 68, 2006.
189.S. I. Dincer, A. Demir, A. Sayar, M. Z. Gunluoglu, H. V. Kara, and A. Gurses, “Surgical treatment of pulmonary hydatid disease: a comparison of children and adults,”Journal of Pediatric Surgery, vol. 41, no. 7, pp. 1230–1236, 2006.
190.E. Pozio, G. la Rosa, K. D. Murrell, and J. R. Lichtenfels, “Taxonomic revision of the genus Trichinella,”Journal of Parasitology, vol. 78, no. 4, pp. 654–659, 1992.
191.D. D. Despommier, “How does Trichinella spiralis make itself at home?”Parasitology Today, vol. 14, no. 8, pp. 318–323, 1998.
192.D. Khemasuwan, C. F. Farver, and A. C. Mehta, “Parasites of the air passages,”Chest, vol. 145, no. 4, pp. 883–895, 2014.
193.F. Bruschi and K. D. Murrell, “New aspects of human trichinellosis: the impact of new Trichinella species,”Postgraduate Medical Journal, vol. 78, no. 915, pp. 15–22, 2002.
194.F. S. Pu, “X-ray manifestations of trichinosis on chest radiograph (analysis of 15 cases),”Chinese Journal of Radiology, vol. 23, no. 1, pp. 21–22, 1989.
195.F. Bruschi and K. Murrell, “Trichinellosis,” inTropical Infectious Diseases: Principles, Pathogens and Practice, Volume II, R. L. Guerrant, D. H. Walker, and P. F. Weller, Eds., pp. 917–925, Churchill Livingstone (Elsevier Science Health Science Division), Philadelphia, Pa, USA, 1999.
196.E. Engvall and I. Ljungstrom, “Detection of human antibodies to Trichinella spiralis by enzyme linked immunosorbent assay, ELISA,”Acta Pathologica, Microbiologica, et Immunologica Scandinavica, vol. 83, no. 3, pp. 231–237, 1975.
197.D. D. Colwell, F. Dantas-Torres, and D. Otranto, “Vector-borne parasitic zoonoses: emerging scenarios and new perspectives,”Veterinary Parasitology, vol. 182, no. 1, pp. 14–21, 2011.
198.L. Polley, “Navigating parasite webs and parasite flow: emerging and re-emerging parasitic zoonoses of wildlife origin,”International Journal for Parasitology, vol. 35, no. 11-12, pp. 1279–1294, 2005.
199.R. Kuchta, J. Brabec, P. Kubáčková, and T. Scholz, “Tapeworm Diphyllobothrium dendriticum (Cestoda) emerging human parasites?”PLoS Neglected Tropical Diseases, vol. 7, no. 12, Article ID e2535.
200.H. Hakimi, S. Kawai, and S. Kawazu, “Molecular epidemiology of the emerging human malaria parasite, ‘Plasmodium knowlesi’,”Tropical Parasitology, vol. 4, no. 1, pp. 20–24, 2014.